David J Pasta
Overview
Explore the profile of David J Pasta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
2951
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Szczesniak R, Andrinopoulou E, Li H, Jain R, Mayer-Hamblett N, Ostrenga J, et al.
J Cyst Fibros
. 2025 Feb;
PMID: 39929763
Background: Increased variability in forced expiratory volume in 1 s of % predicted (FEVpp) has been associated with accelerated lung function decline in individuals with cystic fibrosis (CF). Lung function...
2.
Szczesniak R, Andrinopoulou E, Su W, Afonso P, Burgel P, Cromwell E, et al.
Ann Am Thorac Soc
. 2023 Mar;
20(7):958-968.
PMID: 36884219
Studies estimating the rate of lung function decline in cystic fibrosis have been inconsistent regarding the methods used. How the methodology used impacts the validity of the results and comparability...
3.
Morgan W, VanDevanter D, Pasta D, Foreman A, Wagener J, Konstan M
J Pediatr
. 2023 Jan;
255:265.
PMID: 36653281
No abstract available.
4.
Sawicki G, Konstan M, McKone E, Moss R, Lubarsky B, Suthoff E, et al.
Pulm Ther
. 2022 Nov;
8(4):385-395.
PMID: 36319933
Introduction: Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. Approximately 5% of people with CF have residual function (RF)...
5.
Ohayon M, Thorpy M, Carls G, Black J, Cisternas M, Pasta D, et al.
Sleep Med
. 2021 Jul;
84:405-414.
PMID: 34304148
Objective/background: The real-world experience of people with narcolepsy is not well understood. Patients/methods: The Nexus Narcolepsy Registry (NCT02769780) is a longitudinal, web-based patient registry of self-reported data from adults with...
6.
Thorpy M, Ohayon M, Carls G, Black J, Pasta D, Hyman D, et al.
Sleep Med
. 2021 Jul;
84:380-388.
PMID: 34247126
Background: The aim of this study was to evaluate the impact of different therapy regimens, including sodium oxybate (SXB)-containing regimens, on patient-reported outcomes (PROs) in people with narcolepsy. Methods: Online...
7.
Flume P, Fischer Biner R, Downey D, Brown C, Jain M, Fischer R, et al.
Lancet Respir Med
. 2021 Feb;
9(7):733-746.
PMID: 33581080
Background: Tezacaftor-ivacaftor is an approved cystic fibrosis transmembrane conductance regulator (CFTR) modulator shown to be efficacious and generally safe and well tolerated over 8-24 weeks in phase 3 clinical studies...
8.
Konstan M, Pasta D, VanDevanter D, Wagener J, Morgan W
Pediatr Pulmonol
. 2021 Jan;
56(5):823-836.
PMID: 33434406
The Epidemiologic Study of Cystic Fibrosis (ESCF) was a prospective observational study of over 32,000 people with cystic fibrosis (CF) from 250 clinical care sites in North America from 1994...
9.
Dasenbrook E, Fink A, Schechter M, Sanders D, Millar S, Pasta D, et al.
J Cyst Fibros
. 2019 Dec;
19(4):527-533.
PMID: 31870629
Rationale: The prevalence of adults living with cystic fibrosis (CF) who have early-stage lung disease is increasing. Objectives: Describe the prevalence and evaluate spirometric risk factors associated with the subgroup...
10.
Wagener J, VanDevanter D, Konstan M, Pasta D, Millar S, Morgan W
Pediatr Pulmonol
. 2019 Nov;
55(3):828-834.
PMID: 31746561
Background: In cystic fibrosis, observation of a lung function drop (as percent predicted forced expiratory volume in 1 s [FEV ]; ppFEV ) frequently precedes pulmonary exacerbation (PEx) diagnosis. Recovery...